ATOS
Price
$0.86
Change
+$0.02 (+2.38%)
Updated
May 2 closing price
Capitalization
110.49M
14 days until earnings call
ZIVO
Price
$13.79
Change
-$4.21 (-23.39%)
Updated
May 2 closing price
Capitalization
51.84M
Ad is loading...

ATOS vs ZIVO

Header iconATOS vs ZIVO Comparison
Open Charts ATOS vs ZIVOBanner chart's image
Atossa Therapeutics
Price$0.86
Change+$0.02 (+2.38%)
Volume$528.15K
Capitalization110.49M
Zivo Bioscience
Price$13.79
Change-$4.21 (-23.39%)
Volume$557
Capitalization51.84M
ATOS vs ZIVO Comparison Chart
Loading...
ATOS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ATOS vs. ZIVO commentary
May 05, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ATOS is a Hold and ZIVO is a Hold.

Ad is loading...
COMPARISON
Comparison
May 05, 2025
Stock price -- (ATOS: $0.86 vs. ZIVO: $13.79)
Brand notoriety: ATOS and ZIVO are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ATOS: 84% vs. ZIVO: 86%
Market capitalization -- ATOS: $110.49M vs. ZIVO: $51.84M
ATOS [@Biotechnology] is valued at $110.49M. ZIVO’s [@Biotechnology] market capitalization is $51.84M. The market cap for tickers in the [@Biotechnology] industry ranges from $306.3B to $0. The average market capitalization across the [@Biotechnology] industry is $2.29B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ATOS’s FA Score shows that 1 FA rating(s) are green whileZIVO’s FA Score has 0 green FA rating(s).

  • ATOS’s FA Score: 1 green, 4 red.
  • ZIVO’s FA Score: 0 green, 5 red.
According to our system of comparison, ATOS is a better buy in the long-term than ZIVO.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ATOS’s TA Score shows that 5 TA indicator(s) are bullish.

  • ATOS’s TA Score: 5 bullish, 5 bearish.

Price Growth

ATOS (@Biotechnology) experienced а +13.12% price change this week, while ZIVO (@Biotechnology) price change was -26.66% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.30%. For the same industry, the average monthly price growth was +8.07%, and the average quarterly price growth was -4.75%.

Reported Earning Dates

ATOS is expected to report earnings on Aug 18, 2025.

ZIVO is expected to report earnings on Mar 18, 2025.

Industries' Descriptions

@Biotechnology (+4.30% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ATOS($110M) has a higher market cap than ZIVO($51.8M). ATOS YTD gains are higher at: -9.395 vs. ZIVO (-35.860). ZIVO has higher annual earnings (EBITDA): -13.66M vs. ATOS (-29.46M). ATOS has more cash in the bank: 74.8M vs. ZIVO (159K). ATOS has less debt than ZIVO: ATOS (0) vs ZIVO (377K). ZIVO has higher revenues than ATOS: ZIVO (79K) vs ATOS (0).
ATOSZIVOATOS / ZIVO
Capitalization110M51.8M212%
EBITDA-29.46M-13.66M216%
Gain YTD-9.395-35.86026%
P/E RatioN/AN/A-
Revenue079K-
Total Cash74.8M159K47,044%
Total Debt0377K-
FUNDAMENTALS RATINGS
ATOS vs ZIVO: Fundamental Ratings
ATOS
ZIVO
OUTLOOK RATING
1..100
5050
VALUATION
overvalued / fair valued / undervalued
1..100
29
Undervalued
82
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
100100
PRICE GROWTH RATING
1..100
5661
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
85n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ATOS's Valuation (29) in the Medical Specialties industry is somewhat better than the same rating for ZIVO (82) in the null industry. This means that ATOS’s stock grew somewhat faster than ZIVO’s over the last 12 months.

ATOS's Profit vs Risk Rating (100) in the Medical Specialties industry is in the same range as ZIVO (100) in the null industry. This means that ATOS’s stock grew similarly to ZIVO’s over the last 12 months.

ATOS's SMR Rating (100) in the Medical Specialties industry is in the same range as ZIVO (100) in the null industry. This means that ATOS’s stock grew similarly to ZIVO’s over the last 12 months.

ATOS's Price Growth Rating (56) in the Medical Specialties industry is in the same range as ZIVO (61) in the null industry. This means that ATOS’s stock grew similarly to ZIVO’s over the last 12 months.

ATOS's P/E Growth Rating (100) in the Medical Specialties industry is in the same range as ZIVO (100) in the null industry. This means that ATOS’s stock grew similarly to ZIVO’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ATOS
RSI
ODDS (%)
Bearish Trend 3 days ago
88%
Stochastic
ODDS (%)
Bearish Trend 3 days ago
90%
Momentum
ODDS (%)
Bullish Trend 3 days ago
75%
MACD
ODDS (%)
Bullish Trend 3 days ago
75%
TrendWeek
ODDS (%)
Bullish Trend 3 days ago
78%
TrendMonth
ODDS (%)
Bullish Trend 3 days ago
81%
Advances
ODDS (%)
Bullish Trend 5 days ago
80%
Declines
ODDS (%)
Bearish Trend 19 days ago
89%
BollingerBands
ODDS (%)
Bearish Trend 3 days ago
90%
Aroon
ODDS (%)
Bearish Trend 3 days ago
90%
View a ticker or compare two or three
Ad is loading...
ATOS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
NTOIY5.260.10
+1.94%
Neste OYJ
PNGAY12.060.14
+1.17%
Ping An Insurance (Group) Company of China Ltd.
THKLY12.190.11
+0.91%
THK Co., Ltd.
BNTGY13.340.09
+0.68%
Brenntag SE
SYHBF0.23N/A
-0.22%
Skyharbour Resources Ltd.

ZIVO and

Correlation & Price change

A.I.dvisor tells us that ZIVO and APLM have been poorly correlated (+28% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that ZIVO and APLM's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ZIVO
1D Price
Change %
ZIVO100%
-23.39%
APLM - ZIVO
28%
Poorly correlated
-3.52%
LGVN - ZIVO
24%
Poorly correlated
N/A
MDXXF - ZIVO
24%
Poorly correlated
N/A
AKRO - ZIVO
23%
Poorly correlated
-0.97%
ATOS - ZIVO
23%
Poorly correlated
+1.47%
More